Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts.
about
Current vaccine trials in glioblastoma: a reviewCARs in chronic lymphocytic leukemia -- ready to driveIdentification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingT-cell receptor gene therapy--ready to go viral?T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.T-cell-based therapies for malignancy and infection in childhood.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancerProgram death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.Targeted Therapy of Ewing's Sarcoma.Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunityEfficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysisImmunologic privilege in the central nervous system and the blood-brain barrier.HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.Making Better Chimeric Antigen Receptors for Adoptive T-cell TherapyA pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyTumor immune therapy: lessons from infection and implications for cancer - can IL-7 help overcome immune inhibitory networks?Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.Immune-based therapies for childhood cancer.Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.Adoptive therapy with CAR redirected T cells for hematological malignancies.Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.CARs on track in the clinic.Chimeric Antigen Receptor Therapy for B-cell Malignancies.Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity.IL-2 and Beyond in Cancer Immunotherapy.Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysisCAR T Cell Therapy for Neuroblastoma
P2860
Q26828965-90EDC3BE-2D96-4ABB-B4E6-01D3A7C58ED0Q26830526-2FDADA59-B452-4230-ABE0-1D7C13842216Q27334215-55FBF14F-8371-455A-A80B-F1F4F2E5BFA4Q28081611-D3C89F45-305E-4BEA-8650-DBBA616528ABQ33530527-3A99918D-9530-4F28-824F-F8367B1E7C53Q33750862-2DAA604E-2E51-4A2F-B7E0-DFDAEF0FB219Q33993529-6561B12F-9E5C-45BD-9E6B-038CEA276DBCQ34193534-36BCA813-3D75-44E5-95D3-C4BF50E512FBQ34262377-4BF008F8-EAF5-406D-8A3B-EE689D121A1DQ35220386-0503EC27-C3AA-458C-917A-9868862A3B61Q35588434-7EAD14E8-17D1-4EB2-9E9D-23E90BB66970Q36545348-1E8E18BF-6423-48B2-9478-E13DC86F4C75Q36684162-8726407E-B90D-49D8-981B-FA34731D01F9Q36740297-B8C13130-04EA-4332-8226-A2D625B1AA27Q36830759-ACA55669-9D58-42C1-999C-27C9AD9CF97AQ37366098-B89584B9-A70C-4FFA-9EC7-FC9681A6756CQ37762226-0110221D-2737-43BD-8BAA-4F0B620380C7Q37919880-F79445F8-1855-4E66-8D84-A7B2A630479DQ38035043-E884C457-C38F-4B10-A85E-F33A24D4C1DEQ38263108-D9477366-EFEE-4F9B-9063-CABE859AE5B7Q38756413-15CF7F14-E727-4650-863F-126404257974Q38786628-54520346-977A-4AEB-84F9-61ED4F32FA42Q39564978-F18ADDA4-0AC4-4BF4-97A7-34475D0B0EB1Q39718346-C4B6A845-B39A-4D35-8939-91A18E79AA9CQ42427577-ED90D839-33E0-4D94-8DE5-6080CBD285DAQ42559059-3148D012-7289-4230-B75A-3A4C2E215176Q42649114-B38FEBE3-B928-4BED-9E9B-CBEA840CDB71Q42766326-A366B269-00AB-48A6-B294-D64A3BE434D5Q45870666-D5203F89-6983-4667-BB18-6C98A9D4F94CQ47152771-A05C297E-5EA2-485B-A565-036A4E2AF2ADQ50004232-AA33B6F5-5681-4C90-9A40-A5FC9D842EC1Q52775663-7CA256EE-883F-4850-9434-9C0746A5424EQ58695003-1A4D3BC4-30E6-4E11-8782-A208AD85049AQ59127901-CF7E4188-92C6-4DE6-8D37-7BACDAA14FE7
P2860
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@en
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@nl
type
label
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@en
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@nl
prefLabel
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@en
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@nl
P2093
P2860
P1433
P1476
Harnessing the physiology of l ...... herapy in lymphoreplete hosts.
@en
P2093
Crystal L Mackall
Joanna Meadors
Martin Guimond
Yongzhi Cui
P2860
P304
P356
10.1182/BLOOD-2009-03-212134
P407
P577
2009-08-24T00:00:00Z